Macular Edema - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 59 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Macular Edema - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Macular Edema - Pipeline Review, H2 2014', provides an overview of the Macular Edema's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Macular Edema and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Macular Edema
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Macular Edema and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Macular Edema
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Macular Edema Overview 7
Therapeutics Development 8
Pipeline Products for Macular Edema - Overview 8
Pipeline Products for Macular Edema - Comparative Analysis 9
Macular Edema - Therapeutics under Development by Companies 10
Macular Edema - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Macular Edema - Products under Development by Companies 14
Macular Edema - Companies Involved in Therapeutics Development 15
F. Hoffmann-La Roche Ltd. 15
Allergan, Inc. 16
Santen Pharmaceutical Co., Ltd. 17
Pfizer Inc. 18
Promedior, Inc. 19
Inotek Pharmaceuticals Corporation 20
Taiwan Liposome Company, Ltd. 21
AlphaMab Co., Ltd 22
Macular Edema - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ranibizumab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
betamethasone - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
beclomethasone dipropionate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
dexamethasone SR - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
celecoxib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Inhibit PARP - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PRM-167 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ranibizumab biosimilar - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Macular Edema - Recent Pipeline Updates 43
Macular Edema - Dormant Projects 48
Macular Edema - Discontinued Products 49
Macular Edema - Product Development Milestones 50
Featured News & Press Releases 50
Feb 25, 2014: NICE gives green light to treatment for macular oedema in final guidance 50
Feb 24, 2014: Regeneron Announces FDA Acceptance of EYLEA (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion 50
Dec 27, 2013: NICE gives green light to treatment for macular oedema in final draft guidance 51
Dec 23, 2013: TLC receives FDA IND approval for Sustained Release Macular Disease Drug 52
Nov 22, 2013: EYLEA Injection Approved For The Treatment of Macular Edema Following Central Retinal Vein Occlusion In Japan 52
Oct 21, 2013: Regeneron Reports Positive Phase 3 Data for EYLEA (aflibercept) Injection in Macular Edema Following Branch Retinal Vein Occlusion 53
Sep 27, 2013: New data for Novartis drug Lucentis reinforces transformational efficacy and well-established safety profile across four indications 54
Aug 29, 2013: EYLEA Injection Approved in Europe for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion 55
Jul 26, 2013: EYLEA Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe 56
May 21, 2013: Novartis's Ranibizumab Receives NICE Recommendation For Treatment Of Macular Edema 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products under Development for Macular Edema, H2 2014 8
Number of Products under Development for Macular Edema - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 15
Macular Edema - Pipeline by Allergan, Inc., H2 2014 16
Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 17
Macular Edema - Pipeline by Pfizer Inc., H2 2014 18
Macular Edema - Pipeline by Promedior, Inc., H2 2014 19
Macular Edema - Pipeline by Inotek Pharmaceuticals Corporation, H2 2014 20
Macular Edema - Pipeline by Taiwan Liposome Company, Ltd., H2 2014 21
Macular Edema - Pipeline by AlphaMab Co., Ltd, H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Macular Edema Therapeutics - Recent Pipeline Updates, H2 2014 43
Macular Edema - Dormant Projects, H2 2014 48
Macular Edema - Discontinued Products, H2 2014 49